DEF: Precision BioSciences Sets 2026 Annual Meeting Date, Proposes Director Elections

Precision BioSciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, detailing proposals including director elections, auditor ratification, executive compensation, and equity plan amendments.

Summary

• Precision BioSciences, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 21, 2026, at 10:00 a.m. Eastern Time.
• The meeting will cover several key proposals, including the election of two Class I directors, Melinda Brown and Geno Germano, for terms expiring in 2029.
• Stockholders will also vote on ratifying the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026.
• An advisory vote on the compensation of named executive officers (say-on-pay) is also on the agenda.
• The company is seeking approval to amend and restate its 2019 Incentive Award Plan to increase the number of available shares by 3,800,000.
• Additionally, a proposal to amend the Certificate of Incorporation to provide for officer exculpation, as permitted by Delaware law, will be presented.
• A proposal to adjourn the meeting, if necessary, to solicit additional proxies is also included.
• The record date for determining stockholders entitled to vote is March 25, 2026, with 25,803,199 shares of common stock outstanding.
• Proxy materials are being made available over the Internet, with voting options including internet, telephone, and mail.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and forward-looking plans for talent management and director elections, with no significant negative financial news or immediate operational concerns highlighted.

Positives

• The company is proactively engaging stockholders by providing proxy materials and clear voting instructions.
• The proposed slate of directors includes individuals with extensive experience in finance, accounting, and the biotechnology/pharmaceutical industry.
• The company is seeking to enhance its ability to attract and retain talent through an amendment to its 2019 Incentive Award Plan.
• The proposed officer exculpation amendment aligns with Delaware law and aims to attract and retain key executive talent.
• The company has a robust corporate governance structure with independent directors and established board committees.
• The company successfully raised $75 million in November 2025, extending its cash runway through 2028 and supporting multiple clinical inflection points.
• Key advancements in 2025 included positive Phase 1 data for PBGENE-HBV and progress on the PBGENE-DMD IND filing and Phase 1/2 FUNCTION-DMD trial.
• The company reported a lower voluntary turnover rate than the industry average, indicating employee retention efforts are effective.

Negatives

• The proposed amendment to the 2019 Incentive Award Plan seeks a significant increase in shares (3,800,000), which will increase dilution.
• The proposed officer exculpation amendment failed to pass at the 2025 annual meeting, despite strong support (95% of votes cast), indicating a hurdle in achieving the required majority of outstanding shares.
• The company's stock options granted under the 2019 Plan are currently 'underwater' with a weighted average exercise price of $198.64, significantly above the current stock price.
• The company has experienced net losses in recent fiscal years (e.g., $45,724 thousand in 2025, $61,319 thousand in 2023), typical for a clinical-stage company but indicative of ongoing financial burn.
• The pay versus performance analysis shows a lack of consistent alignment between compensation actually paid and total shareholder return from 2023 to 2024, suggesting compensation is not solely driven by stock performance in that period.

Risks

• The company's ability to attract and retain talent may be adversely impacted if the proposed officer exculpation protections are not implemented.
• The proposed increase in the equity incentive plan shares could lead to increased dilution for existing stockholders.
• The company's reliance on future capital raises to fund operations and clinical development presents ongoing financial risk.
• The company's stock price has been significantly below the exercise price of outstanding options, potentially impacting employee morale and retention if not addressed.
• The company faces risks associated with the inherent uncertainties of clinical development, including regulatory approvals, trial outcomes, and market adoption.

Future Outlook

The company is focused on advancing its clinical development programs, including PBGENE-HBV and PBGENE-DMD, with data updates expected throughout 2026. The successful capital raise in November 2025 is expected to extend the cash runway through multiple clinical inflection points between 2026 and the end of 2028.

Management Comments

• "Your vote is important to us. Please act as soon as possible to vote your shares."
• "It is important that your shares be represented at the meeting whether or not you plan to attend the Annual Meeting via the Internet."
• "We believe that providing our proxy materials over the Internet expedites stockholders receipt of proxy materials, lowers costs and reduces the environmental impact of the Annual Meeting."
• "We believe that the continued use of the 2019 Plan is essential to our success."
• "Limiting concern about personal liability will empower officers to best exercise their business judgment in furtherance of stockholder interests without the distraction of potentially being subject to claims following actions taken in good faith."
• "Our Board of Directors believes that limiting concern about personal liability will empower officers to best exercise their business judgment in furtherance of stockholder interests without the distraction of potentially being subject to claims following actions taken in good faith."

Industry Context

StockSavvy.ai notes that Precision BioSciences' proxy statement reflects common practices in the biotechnology sector, particularly regarding the need for equity incentives to attract and retain specialized talent in a competitive market. The proposed increase in share availability for the incentive plan is a typical strategy to support growth and development, though it carries the inherent risk of dilution. The focus on clinical development milestones and capital raises aligns with the industry's funding and progress cycles.

Comparison to Industry Standards

• The company's 3-year average net burn rate of 4.8% is positioned between the median (3.8%) and 75th percentile (5.7%) compared to 158 biotechnology companies with $50-500 million market capitalization.
• The projected overhang of 17.2% (or 20.0% including an inducement plan) if the share increase is approved, is lower than the median of 20.3% for similarly situated companies.
• The company's TSR from December 31, 2023, to December 31, 2025, was consistent with peers like Editas Medicine, Inc., Prime Medicine, Inc., Verve Therapeutics, Inc., Sangamo Therapeutics, Inc., Intellia Therapeutics, Inc., and Metagenomi, Inc., suggesting that stock performance in the gene editing sector is largely driven by sector-wide trends rather than individual company operational performance for pre-commercial companies.
• The company's net loss position in 2025 and 2023 is typical for clinical-stage biotechnology companies, aligning with industry norms where significant investment in R&D precedes revenue generation.

Corporate Governance

Related Party Transactions

• Dr. Stanley R. Frankel, a director, entered into a consulting agreement in June 2025, providing consulting, advisory, and related services through June 30, 2026, with monthly retainers and hourly rates for additional services. This agreement was approved in accordance with the company's related person transaction policy.

Stakeholder Impact

• Shareholders: Voting on director elections, executive compensation, equity plan dilution, and corporate governance changes. The proposed equity plan amendment could lead to increased dilution.
• Management and Employees: Potential for continued equity incentives to attract and retain talent, and increased protection from personal liability for officers.
• Auditors: Continued engagement of Deloitte & Touche LLP for 2026, subject to ratification.
• Board of Directors: Election of new directors and continuation of existing governance structures.

Next Steps

• Stockholders to vote on the proposals presented at the Annual Meeting.
• Election of directors and ratification of auditor appointment.
• Approval of executive compensation and the amended 2019 Incentive Award Plan.
• Approval of the amendment to the Certificate of Incorporation for officer exculpation.
• Potential adjournment of the Annual Meeting if necessary.
• Continued advancement of clinical development programs (PBGENE-HBV, PBGENE-DMD) with data updates expected in 2026.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting and does not contain new material financial results or strategic shifts that would warrant a buy or sell recommendation. It outlines standard corporate governance proposals and plans for talent management. While the company is advancing its pipeline and has secured funding, the inherent risks of clinical-stage biotechnology and the potential for dilution from equity awards suggest a 'hold' position pending further operational and clinical developments.

Keywords

Precision BioSciences, Proxy Statement, Annual Meeting, Stockholders, Director Election, Executive Compensation, Incentive Award Plan, Officer Exculpation, Deloitte & Touche LLP, Biotechnology, Gene Editing